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Abstract
Objective—Extensive joint hypermobility, lower serum cartilage oligomeric matrix protein
(COMP), and early-onset osteoarthritis (OA) are phenotypes of inherited pseudoachondroplasia
(PSACH) and multiple epiphyseal dysplasia (MED). However, few studies have evaluated the
association between articular hypermobility and primary OA. Therefore, we evaluated this
association and tested the hypothesis that COMP level is associated with hypermobility in OA and
non-OA individuals.
Methods—Two separate cohorts were available for analysis, the extended CARRIAGE family
and a subset of the GOGO sib pair cohort. In the CARRIAGE family, we performed hand and
knee examinations, hypermobility evaluations (Beighton criteria), and obtained sera for COMP
and hyaluronan (HA). COMP and HA, extensive joint radiographic and hypermobility data were
also available for the GOGO cohort.
Results—The prevalence of hypermobility was 13% in the CARRIAGE and (5%) in the GOGO
cohort. In the CARRIAGE family, hypermobility was associated with a significantly lower
prevalence of hand (especially proximal interphalangeal joint) and knee OA, and lower mean
serum COMP in both the total cohort and non-hand OA subgroups. These results were further
validated in the GOGO subsets without radiographic OA where hypermobility was also associated
with a significantly lower mean serum COMP (p<0.01). Serum HA did not differ on the basis of
hypermobility in either cohort.
Conclusions—We report an inverse relationship of hypermobility, hand and knee OA, and
show that hypermobility is associated with lower serum COMP levels. Genetic variations of the
COMP gene may account for some subgroups of benign joint hypermobility.
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Introduction
Osteoarthritis (OA) is a multifactorial complex disorder associated with chronic disability
and various risk factors (1), including age, obesity, female gender, muscle weakness, joint
malalignment, and genetic predisposition (2). Joint hypermobility due to ligamentous laxity
has empirically been regarded to be a risk factor for OA (3), although results of the few
studies to date have been conflicting (Table 1). The true prevalence and risk for
musculoskeletal disorders associated with hypermobility is unknown.
Joint hypermobility, estimated to affect approximately 5% to 25% of the population
depending on age, sex, and race (4), is observed as both a lone benign trait and as one
manifestation of a variety of severe but rare heritable disorders including Marfan syndrome
(1 in 12,000), Ehlers-Danlos syndrome (1 in 5,000), osteogenesis imperfecta (1 in 100,000),
pseudoachondroplasia (PSACH, less than 1 in 200,000 in the USA), and some forms of
multiple epiphyseal dysplasia (MED, 1 in 10,000) (5, 6). The latter conditions, PSACH and
MED, are characterized by prominent joint laxity and variable short stature, short
extremities, and early-onset OA, especially in the hips and knees, and are due to mutations
in genes coding for cartilage oligomeric matrix protein (COMP) (7). During the
ascertainment of the CARRIAGE (CARolinas Region Interaction of Aging Genes and
Environment) family, we noticed joint hypermobility in many members. We therefore
investigated the association between joint hypermobility and clinical OA phenotypes, and
the OA-related serum biomarkers, COMP, and hyaluronan (HA). We then validated our
results in a larger family-based study (GOGO).
Methods
Study Populations
The CARRIAGE family study is a prospective family-based longitudinal study of the
interactions between aging, genetic susceptibility, and environmental risk pertaining to the
development of several age-related chronic diseases including OA, cardiovascular disease,
and eye diseases (glaucoma, and macular degeneration). This family came to be studied in
the context of health fairs we were requested to conduct at several large family reunions.
The extended family described here is of mixed African American and native American
ancestry and one of the most extensively pedigreed existing families in the United States
comprising nine generations with 3357 pedigreed members, and originating from one
founder born in the 1700s (8). Ascertainment of 350 family members was conducted during
three family reunions from 2002–2006. Ascertainment included physician-performed
examinations for hand OA and joint hypermobility (n=287), and knee OA (n=120). Height
and weight were measured, and general medical history ascertained including a query or
examination for blue sclerae. The majority of these participants (n=278) also consented to
blood sampling. For purposes of these analyses, we excluded 2 participants with known
clinical rheumatoid arthritis and subjects younger than 25 years of age (n=5) to avoid
potential confounding of the biomarker measures by cartilage growth plate metabolism (9,
10). After these exclusions, a total of 280 participants provided full clinical hand data, a total
of 271 had both clinical hand data and biomarker data, and of these, 115 participants also
had clinical knee examination data. Written informed consent was obtained from each
participant and the study was conducted with the approval of the Duke Institutional Review
Board.
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The GOGO (Genetics of Generalized Osteoarthritis) cohort is a large sample of Caucasian
sibling pairs and nuclear family members ascertained through a collaborative consortium of
seven sites in the USA and UK (11). Full biomarker data, Beighton scores, and hand, knee,
and hip radiographic OA data were available for 708 individuals from two of the sites (Duke
University, Durham, NC and University of North Carolina at Chapel Hill, NC, USA). There
were no individuals in either the CARRIAGE family or the GOGO cohort with excessively
short stature or radiographic features (in the case of the GOGO cohort) suggestive of
PSACH or MED, nor anyone with blue sclerae suggestive of osteogenesis imperfecta.
Survey of joint symptoms in the CARRIAGE family
Information was obtained on self-reported joint symptoms on the basis of the following
question: “Which of the following joints have bothered you in the last year?” The surveyed
joint-sites included hands, knees, hips, spine (neck, upper, lower back), ankles, shoulders,
elbows, wrists, and big toes.
Definitions of clinical hand and knee OA outcomes in the CARRIAGE family
OA outcomes in the CARRIAGE family are listed and described in Table 2 and included
clinical hand OA by modified American College of Rheumatology (ACR) criteria (12),
clinical hand OA by GOGO criteria (11, 13), and clinical knee OA by ACR criteria (14). A
Non-Hand OA subgroup in the CARRIAGE family was defined on the basis of not meeting
the clinical modified hand OA ACR criteria or the clinical hand OA GOGO criteria.
Definitions of non-OA subgroups in the GOGO cohort
The non-OA subgroups were defined using the available clinical data for the hand as well as
on the basis of Kellgren Lawrence (15) grade <2 radiographic OA of the hands, knees or
hips (Table 2).
Beighton criteria for hypermobility
Hypermobility was determined according to the criteria established by Beighton et al in
1973 (16) that have high inter- and intra-rater reliability (17). Patients were graded on a 0–9
point scale based on their ability to achieve the following: (a) passive dorsiflexion of the
fifth finger ≥90°; (b) passive apposition of the thumb to the forearm; (c) hyperextension of
the elbow ≥10°; (d) hyperextension of the knee ≥10°; and e) ability to rest the palms flat on
the floor with straight knees. Beighton scores were analyzed as continuous traits and as
binary traits; for binary trait analyses, patients were considered as exhibiting hypermobility
if they scored 4 or more out of 9 points (16).
Biomarker analyses
Serum was isolated, aliquoted and stored within 4 hours of blood collection at −80°C until
biomarker analyses were performed. Duplicate serum biomarker assays were performed for
each sample, and analyses were repeated as necessary for samples with a >15% coefficient
of variation (CV). COMP was measured by an in-house sandwich ELISA method as
previously described, using monoclonal antibodies 17C10 (epitope in the EGF-like domain)
and 16F12 (epitope in the NH2-terminal domain) against human COMP (18). The minimum
detection limit is 120 ng/ml. Intra-assay and inter-assay CVs were < 5.8% and 8.7%,
respectively. HA was measured by an enzyme-linked binding protein assay (Corgenix Inc.
Westminster, Colorado, USA). The assay uses enzyme-conjugated hyaluronic acid binding
protein (HABP) from bovine cartilage to specifically capture HA from human serum. The
minimum detection limit is established at 10 ng/ml. Intra-assay and inter-assay CVs were
<4.7% and 7.0%, respectively.
Chen et al. Page 3














The Chi-square test was used to compare the prevalence of joint symptoms and prevalence
of OA by hypermobility status. The Mann-Whitney U test was used to assess the mean
numbers of OA joints according to hypermobility status. The serum biomarker
concentrations were logarithmically transformed to meet requirements of normality for
parametric statistical analyses. Two-sample t test was used to evaluate for differences in
mean biomarker concentrations between the hypermobility and non-hypermobility groups.
One-Way ANOVA with the Tukey-Kramer multiple comparison test was used to evaluate
the relationship of Beighton scores with concentrations of biomarkers. Generalized
Estimating Equations (GEE) were used to control for the dependency due to familial
clustering of CARRIAGE family members and GOGO nuclear families (SAS version 9.1,
SAS Institute, Cary, NC). For the CARRIAGE family, we classified individuals into eight
clusters based on their relationship to eight members descended from the founder of the
CARRIAGE family. For the GOGO cohort, individuals were clustered by family. Age
adjustment was performed for all analyses and additional adjustment for BMI was
performed for all analyses involving prevalence of clinical or radiographic OA. Adjustment
for hand OA status was included in the logistic regression analysis of hypermobility and
COMP in the CARRIAGE family. Analyses of hypermobility and COMP were performed in
the full GOGO sample of patients from two sites (Duke and UNC) and in subgroups without
radiographic OA. Significant results were declared based on a two-sided p-value of <0.05.
Results
Hypermobility and joint symptoms in the CARRIAGE family
Joint hypermobility (Beighton score≥4) was present in 36 (12.9%) of the 280 examined
CARRIAGE family participants. The hypermobility group did not differ significantly by age
or BMI from the non-hypermobility group (Table 3). The age distribution of the 115
participants in the knee-examined subgroup was similar to the group as a whole with a
slightly younger mean age for the hypermobility group, which was not statistically different
from the non-hypermobility group (53.5±14.2 years for hypermobile individuals, 58.3±14.7
years for non-hypermobile individuals, p=0.15). The hypermobility group had a female
predominance compared with the non-hypermobile group. The prevalence of hand and knee
joint symptoms was lower in the hypermobile group, but the prevalence of symptoms in the
other joints systems was similar (Table 3).
Hypermobility and Osteoarthritis in the CARRIAGE family
The hypermobility group in the CARRIAGE family had a consistently lower prevalence of
hand OA by the modified ACR and GOGO criteria, and a lower prevalence of knee OA by
ACR criteria (Table 4). By logistic regression, hypermobility was associated with a
decreased likelihood ratio of hand OA in the CARRIAGE family (p=0.02 by modified ACR
criteria; p=0.008 by GOGO criteria), which remained significant after age and BMI
adjustment (for modified ACR criteria: p=0.024 BMI-adjusted, p=0.043 age-adjusted, and
p=0.047 age and BMI adjusted; for GOGO criteria: p=0.009 BMI-adjusted, p=0.018 age-
adjusted, and p=0.02 age and BMI adjusted) (Table 4). The hypermobility group
demonstrated significantly fewer OA clinically affected PIP joints (p<0.005), and a non-
significant but decreased prevalence of OA of DIP and CMC1 joints. Taking all three hand
joint groups into consideration, hypermobility was significantly inversely associated with
numbers of OA affected joints (Table 4). Hypermobility was also associated with a
decreased likelihood ratio of knee OA (p=0.02; p=0.035 BMI-adjusted, p=0.058 age-
adjusted, and p=0.068 age and BMI adjusted).
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Hypermobility and biomarkers in the CARRIAGE family
Mean (SD) ln serum COMP decreased significantly with increasing hypermobility by
Beighton score: 7.48±0.42 for Beighton score 0; 7.37±0.42 for Beighton score 1–3;
7.29±0.43 for Beighton score≥4 (p=0.034 adjusted for age, Figure 1a). Mean (SD) ln serum
COMP was significantly lower in the hypermobility group (7.29±0.43) vs. the non-
hypermobility group (7.43±0.42) (p=0.05) (Figure 1b); however, mean ln serum HA did not
differ significantly between the two groups (Figure 1c). When adjusted for age and hand OA
status (by clinical GOGO or modified hand ACR criteria), mean ln serum COMP was
marginally significantly lower in the hypermobility group compared with the non-
hypermobility group (by GOGO criteria, p=0.069; by modified hand ACR criteria,
p=0.068). To more clearly define the association of hypermobility and serum COMP,
independent of hand OA status, we analyzed the relationship in the Non-Hand OA subgroup
of the CARRIAGE family. Mean ln serum COMP was also significantly lower in the Non-
Hand OA subgroup with hypermobility compared with the members without hypermobility.
When hand OA was excluded on the basis of clinical GOGO criteria, mean ln serum COMP
levels were 7.26±0.43 in the hypermobility group vs 7.42±0.43 in the non-hypermobility
group (p=0.053 adjusted for age); when hand OA was excluded on the basis of the modified
ACR criteria, mean ln serum COMP was 7.27±0.42 in the hypermobility group vs 7.42±0.41
in the non-hypermobility group (p=0.049 adjusted for age) (Figure 1d and 1e). When
familial clusters were taken into account by the GEE analysis, the inverse association
between, hypermobility (using Beighton score as a continuous covariate) and serum COMP
level remained highly significant (p=0.0035 age-adjusted). When hypermobility was
analyzed as a binary trait (<4 or ≥4), the association was still apparent but less robust
(p=0.082 age-adjusted).
Hypermobility and biomarkers in the GOGO cohort
Joint hypermobility was present in 36 (5%) of the 708 GOGO study participants. In
agreement with the CARRIAGE family results, mean (±SD) ln serum COMP in the GOGO
cohort also decreased significantly with increasing hypermobility by Beighton score:
6.94±0.53 for Beighton score 0; 6.72± 0.53 for Beighton score 1–3; 6.63± 0.54 for Beighton
score≥4 (p< 0.0001, adjusted for age). Mean ln serum COMP was consistently lower in the
hypermobility group compared with the non-hypermobility group (6.60±0.61 vs 6.91±0.53,
p=0.0009; 6.64±0.54 vs 6.90±0.53, p=0.004 adjusted for age). In contrast, before and after
controlling for age, mean ln serum HA was similar in the two groups (3.44±0.88 vs
3.63±0.85, p=0.2; 3.63±0.81 vs 3.62±0.80, p=0.9 adjusted for age). To evaluate the
possibility that OA itself might cause an apparent diminution in manifestations of
hypermobility due to loss of joint range of motion, we repeated the analyses in the
individuals without radiographic OA (rOA). For each joint site, mean ln serum COMP was
significantly lower in association with joint hypermobility (Figure 2). Results for the 251
individuals lacking both hip and knee rOA were similar, with lower serum COMP in the
hypermobile individuals (p=0.002 adjusted for age). In contrast, mean ln serum HA did not
differ on the basis of hypermobility status in the non-rOA groups (data not shown). Similar
to the CARRIAGE family dataset, the GEE analysis for GOGO data revealed a highly
significant inverse association between hypermobility (using Beighton score as a continuous
covariate) and serum COMP level (p<0.0001 age-adjusted). When hypermobility was
analyzed as a binary trait (<4 or ≥4), the inverse association with serum COMP level was
also apparent (p=0.01 age-adjusted).
Discussion
We report evidence for a relationship between serum COMP level and general joint
hypermobility. COMP is a 524 KDa homopentameric non-collagenous glycoprotein derived
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from cartilage and also found in ligaments and tendons (19). Recent in vitro studies have
shown that COMP can interact with collagens I, II, IX, fibronectin, and all matrilins (20–
23), and that COMP can bind to collagens I, II, and IX with high affinity (24). Interestingly,
some autosomal dominant osteochondrodysplasias (PSACH and some MED) are caused by
mutations in COMP that interfere with normal extracellular matrix assembly, which is
thought to contribute to the development of the patient phenotypes (25, 26). Pronounced
hypermobility and low serum COMP are features of these osteochondrodysplasias (27, 28).
Low serum COMP may result from retention of mutant COMP within the rough
endoplasmic reticulum of chondrocytes and tendon cells (29); but not all the COMP-
associated chondrodysplasias appear to be storage diseases (25, 26), so other mechanisms
yet to be defined, such as altered COMP protein or RNA synthesis or stability, may account
for low serum COMP in these chondrodysplasias. By analogy, genetic variation within the
COMP gene might influence both serum COMP levels and ligamentous structure leading to
articular hypermobility phenotypes in the CARRIAGE family and GOGO cohort. Of note,
Jonsson has recently reported linkage of joint hypermobility (dorsiflexion≥90° of either fifth
finger in an Icelandic cohort of 331 subjects) to chromosome 19P 13.3 (LOD score of 3.8),
which is within 16Mb of the COMP gene (30). Also, Hakim et al, has reported autosomal
dominant inheritance of benign joint hypermobility affecting female twins (31).
Our study also demonstrated that generalized articular hypermobility is inversely associated
with clinical hand (PIP) OA and possibly also knee OA. This confirms and extends our
previous results in the GOGO cohort showing that hypermobility was associated with a
lower prevalence of PIP OA and possibly OA in MCP joints. A strength of this study is that
all family members were invited to participate and included, independent of hypermobility
status or signs or symptoms of musculoskeletal problems. Although it is possible that the
healthier family members may have been more likely to attend the family reunions, we
avoided the common selection bias of most other studies related to hypermobility that relied
on clinic based populations with a high prevalence of joint symptoms. These family data
may therefore be more representative of the general population. Our study showed that after
accounting for age, PIP joint and knee OA prevalence was lower in association with joint
hypermobility with a similar trend observed for DIP and CMC1 joint OA. In the previously
reported study of hypermobility in the GOGO cohort, no conclusions could be drawn
regarding hypermobility and DIP joints because study inclusion required OA in at least one
DIP in the proband and one sibling (11, 32). No such inclusion criteria were used in the
CARRIAGE family study and we saw a trend of fewer OA affected DIP joints in association
with hypermobility. It is possible that a larger sample size or radiographic phenotyping
might be necessary for further validation of the inverse relationship of hypermobility and
OA of DIP, MCP and CMC1 joints.
Our results are also in agreement with a recent community-based study of post-menopausal
females showing a reduced risk of radiographic knee OA with joint hypermobility (33).
Preliminary data from another study, a cohort of Icelandic subjects (n=1839) with a 31%
prevalence of any hypermobility, has also shown a reduction in clinical knee OA in
association with hypermobility (Chi square p = 0.04, Dr. Helgi Jonsson personal
communication). Moreover, Jonsson et al reported, in two separate studies, less hand
interphalangeal joint involvement in association with hypermobility (34, 35). In contrast,
some studies have reported a higher prevalence of OA in association with hypermobility.
Decades ago, two studies reported a higher prevalence of OA in individuals with joint
hypermobility from groups of highly selected patients referred for clinical evaluation (3, 36);
however, in one of these studies, different effects were observed for the knee (increased OA)
compared with hand (decreased OA) in association with hypermobility (36). Jonsson et al
also reported more CMC1 joint OA in association with hypermobility (34). Thus, the type
and strength of the effect of hypermobility on OA susceptibility may differ by joint group,
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Although several previous studies have emphasized the association of the benign joint
hypermobility syndrome with musculoskeletal symptoms (37–39), our study showed that
CARRIAGE family members with joint hypermobility had a lower prevalence of self-
reported joint symptoms in their hands and knees than participants without hypermobility.
Moreover, it has been recognized through studies of children and adolescents, that not all
individuals deemed hypermobile have a history of musculoskeletal symptoms and disorders
or go on to develop them in their life (40). In agreement with our study, Larsson et al also
found a lower prevalence of hand symptoms in instrumentalists with lax fingers performing
repetitive fine hand movements compared with their peers with less flexibility (41). The
effect of hypermobility on symptoms may be specific to particular joint groups since
hypermobility appeared to increase low back symptoms in timpani players (41). Thus, again
joint group is one possible factor explaining some of the differences in hypermobility related
symptoms and OA risk.
There are many other possible factors that might explain the reports of conflicting
associations of hypermobility, osteoarthritis and musculoskeletal symptoms. Murray has
suggested that hypermobility alone may not account for musculoskeletal syndromes but that
other cofactors, such as obesity, sedentary lifestyle, or joint overuse may be important
moderators of the symptoms and outcomes of hypermobility (40). Murray has also
suggested that a high risk subgroup of children may exist which would be under recognized
when the typical Beighton score thresholds used for adults are employed for defining
hypermobility. Mechanical joint forces may vary due to ligamentous laxity on a joint
specific basis. It is possible that individuals with hypermobility may moderate their activity
due to pain or joint instability that may reduce the risk of OA. Finally, hypermobile
individuals represent both a phenotypically and genetotypically heterogenous group. In
addition to PSACH and MED (COMP mutations), variable degrees of hypermobility are
associated with other genetic syndromes including among others, Marfan’s syndrome
(fibrillin mutations), and Ehlers Danlos syndromes (mutations of col1A1, col1A2, col3A1,
col5A1, col5A2, ADAMTS2, and tenascin XB) (42). The underlying genetic etiology rather
than hypermobility, may account for the risk of symptoms and OA, but under diagnosis of
these conditions may in part be responsible for the general but erroneous attribution of all
hypermobility with risk of OA. These issues deserve to be further explored in future studies.
Although we obtained the same results from two separate cohorts, some shortcomings
remain. We are limited due to the cross-sectional nature of our study. Therefore, we cannot
completely rule out the possibility that OA masks the manifestations of hypermobility,
although OA seldom affects the wrists or 5th MCP joints that contribute to the Beighton
score. However, in our study, we believe that the inverse association of hypermobility and
OA was not due to waning joint laxity with age and OA because the negative association
persisted after adjustment for age. We considered the possibility that lower COMP in the
hypermobility group might be a manifestation of younger age and fewer OA affected joints
since serum COMP is positively associated with severity of radiographic OA (18, 43).
Therefore, we also analyzed the non-OA participants to evaluate the association of
hypermobility and the biomarkers, COMP and HA. Serum COMP level was consistently
lower in association with hypermobility in both cohorts of non-OA individuals. In contrast,
HA levels, a marker of joint tissue turnover of OA (44), were unchanged in association with
hypermobility. We thus show that the association of hypermobility with lower prevalence of
OA and lower serum COMP, was neither a result of age nor a result of OA masking
hypermobility.
To address the possibility that COMP fragmentation was a cause of lower serum COMP
with hypermobility, we performed additional sandwich ELISAs, and Western blots (data not
shown) on the sera of a test subset of 9 individuals with and without hypermobility, low and
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high COMP, and OA, using three different monoclonal antibodies to the COMP amino-
terminus, middle and carboxy-terminus as described previously (45) (reducing gels for
antibodies of 16F12 and 12C4; nonreducing gel for antibody of 17C10). Specifically, we
evaluated these sera for evidence of COMP fragments between 50–90 kDa as described
previously using polyclonal antibodies against human COMP (46). There were no 50–90
kDa COMP fragments in the sera of any of the test individuals, but COMP fragments of this
size were readily discerned in the positive control (EDTA cartilage extract). ELISA assys
with combinations of these three anti-COMP antibodies also supported the presence of full-
length COMP in the sera (data not shown). Thus, the lower serum COMP level associated
with hypermobility was due to absolute lower level of full-length COMP in the sera rather
than targeted degradation.
In summary, we report the evidence for a relationship between serum COMP level and
general joint hypermobility. In addition, in this extended family of mixed African American
and Native American heritage, we have replicated the results from the GOGO Caucasian sib
pair cohort, in which we demonstrated that general articular hypermobility was inversely
associated with OA of PIP joints. Our study also suggests the possibility of an inverse
association of joint hypermobility and knee OA although this result needs to be validated in
a larger cohort. We hypothesize that hypermobility may decrease biomechanical strain on
joints, which in turn would be protective for hand and knee OA. Hypermobility is a heritable
trait associated with lower serum COMP and COMP mutations in some
osteochondrodystrophies. The results of our study suggest that genetic variation within the
COMP gene may be a candidate to account for benign joint hypermobility, a condition
whose etiology has hitherto been unknown. This study also suggests that the extent of
hypermobility might serve as a quantitative trait for identifying protective alleles for OA.
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Figure 1. The relationship between biomarkers and joint hypermobility in the total cohort (a–c)
and Non-Hand OA subgroups (d–e) of the CARRIAGE family
a) Serum ln COMP (after adjustment for age) and Beighton score separated into 3 groups,
no hypermobility (score 0), moderate hypermobility (score 1–3) and high hypermobility
(score ≥4); b) Serum ln COMP by hypermobility status; c) Serum ln HA by hypermobility
status. Analysis of participants without hand OA was based on d) clinical GOGO criteria
(n=228: n=34 with and n=194 without joint hypermobility); or e) modified ACR criteria
(n=233: n=34 with and n=199 without joint hypermobility). P value calculated by one-way
ANOVA with Tukey multiple comparison (a), or two-sample t test (b–e). Box plots depict
mean, 25th and 75th percentiles, and minimum and maximum. Hypermobility status defined
by Beighton score <4 (Non-hypermobilty) or ≥4 (Hypermobility). COMP = cartilage
oligomeric matrix protein, HA = hyaluronan, NS = non-significant.
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Figure 2. Mean ln COMP by hypermobility status in the Non-OA subgroups of the GOGO
cohort
Analysis of participants without OA of the following specific joint groups: a) hand OA
based on ACR criteria (n=167); b) rOA of DIP joints (n=77); c) rOA of PIP joints (n=135);
d) rOA of CMC1 joints (n=333); e) rOA of knees (n=374); or f) rOA of hips (n=399). P
value (adjusted for age) calculated by two-sample t test with equal variance. Box plots
depict mean, 25th and 75th percentiles, and minimum and maximum. Hypermobility status
defined by Beighton score: <4 (Non-hypermobilty) and ≥4 (Hypermobility). DIP = distal
interphalangeal; PIP = proximal interphalangeal; CMC1 = first carpometacarpal; KL grade =
Kellgren-Lawrence grade radiographic OA (rOA); COMP = cartilage oligomeric matrix
protein
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Table 2










Hand OA - modified*
American College of
Rheumatology (ACR) criteria
1 hard tissue enlargement of two or more of 10 selected joints
2 hard tissue enlargement of two or more DIP joints
3 fewer than three swollen metacarpophalangeal (MCP)
√ (47)
Hand OA - GOGO criteria 1 a minimum of 3 joint bony enlargement (of distal or proximal
interphalangeal joints - DIP and PIP) or first carpometacarpal
(CMC1) squaring, and two of the three joints involving the
same joint group
2 bony enlargement of at least one DIP of digits 2–5
3 bilateral hand involvement
4 ) no more than three swollen MCPs
√ (52)
Non-Hand OA Lacks Hand OA by modified* ACR criteria √ (233) √ (167)
Non-Hand OA Lacks Hand OA by GOGO criteria √ (228)
Non-DIP OA
No radiographic OA based on Kellgren Lawrence grade <2 bilaterally in
all joints of a group
√ (77)
Non-PIP OA √ (135)
Non-CMC1 OA √ (333)
Non-Knee OA
No radiographic OA based on Kellgren Lawrence grade <2 in joint group
bilaterally
√ (374)
Non-Hip OA √ (399)
Non-Knee and Hip OA √ (251)
Knee OA - clinical ACR
criteria
knee pain and a minimum of 3 of 6 other features:
1 age greater than 50 years old




6 absence of palpable warmth
√ (115)
Hypermobility evaluation Beighton criteria treated as a continuous variable (0–9) or as a
dichotomous variable (non-hypermobility <4; hypermobility ≥4)
√ (280) √ (708)
Serum COMP and HA √ (271) √ (708)
*
We did not utilize the ACR hand symptoms and deformity criteria as part of our definition of hand OA, so we refer to these as modified ACR
criteria; COMP=cartilage oligomeric matrix protein; HA=hyaluronan
CARRIAGE family N of 280 is the final number evaluated after excluding 5 under 25 years old and 2 with rheumatoid arthritis
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Table 3
Demographic characteristics of CARRIAGE family study participants (n=280).
Hypermobility (N=36) (Beighton score≥4) Non-hypermobility (N=244) (Beighton score<4) P Value
Age, years 53.27±14.38 56.36±14.64 0.24
BMI (kg/m2) 29.67±6.09 31.23±6.67 0.19
Female % 83.3% (n=30) 66.4% (n=162)
Joint self-reported symptoms N (% of group of 25 total) N (% of group of 224 total)
Hand symptoms 1 (4.0%) 47 (21.0%) 0.02
Knee symptoms 5 (20.0%) 92 (41.1%) 0.03
Hip symptoms 5 (20.0%) 43 (19.2%) 0.92
Spine symptoms 12 (48.0%) 101 (45.1%) 0.78
Ankle symptoms 4 (16.0%) 38 (17.0%) 0.90
Shoulder symptoms 7 (28.0%) 68 (30.4%) 0.80
Elbow symptoms 2 (8.0%) 23 (10.3%) 0.71
Wrist symptoms 3 (12.0%) 30 (13.4%) 0.84
Big toes 2 (8%) 16 (7.1%) 0.87
For evaluation of age and BMI between hypermobility and non-hypermobility groups, P value was generated by unpaired t test
For evaluation of symptoms between hypermobility and non-hypermobility groups, P value was generated by Likelihood ratio Chi-square for joint
self-reported symptoms
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Table 4
Clinical OA status by hypermobility status in the CARRIAGE family.
OA Definitions Hypermobility Group N (%)
by OA Status
Non-Hypermobility Group N
(%) by OA Status
P value P value (adjusted
for age and BMI)
Hand: GOGO Criteria (n=280
evaluated)
1 (2.8%) 42 (17.2%) <0.01 0.02
GOGO criterion 1 1 (2.8%) 57 (23.4%) <0.001 <0.01
GOGO criterion 2 5 (13.9%) 60 (24.6%) 0.13 0.3
GOGO criterion 3 4 (11.1%) 71 (29.1%) 0.01 0.02
Hand: Modified ACR Criteria
(n=280 evaluated)
1 (2.8%) 36 (14.8%) 0.02 0.05
ACR criterion 1 2 (5.6%) 68 (27.9%) <0.005 <0.005
ACR criterion 2 2 (5.6%) 39 (16.0%) 0.06 0.14
Knee: ACR criteria (n=115
evaluated)
3 (12.0%) 31 (34.4%) 0.02 0.07
Joint Site Involvement (n=280
evaluated)
mean ± SD # OA Joints mean ± SD # OA Joints
DIPs 0.22 ± 0.63 0.60 ± 1.35 0.13 0.18
PIPs 0.14 ± 0.49 1.01 ± 1.97 <0.005 0.01
CMC1 0.028 ± 0.17 0.14 ± 0.48 0.2 0.24
DIPs+PIPs+CMC1 0.39 ± 0.99 1.75 ± 3.12 <0.005 0.02
Hypermobility Group = Beighton score ≥4 (total n=36 in the hand examined group and n=25 in the knee examined group); Non-Hypermobility
Group = Beighton score <4 (total n=244 in the hand examined group and n=90 in the knee examined group) GOGO and (modified) ACR criterion
given in Table 2
P value by Likelihood ratio Chi-square test for OA definition; p value by Mann-Whitney test for joint sites; DIP = distal interphalangeal; PIP =
proximal interphalangeal; CMC1 = carpometacarpal
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